Humana Acquires Florida-Based MaxHealth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 14 2026
0mins
Should l Buy HUM?
Source: seekingalpha
- Acquisition Context: Humana's healthcare services unit, CenterWell, has acquired MaxHealth, a Florida-based primary care organization serving over 120,000 patients through a network of 82 clinics, thereby enhancing its market share in Florida.
- Customer Base: MaxHealth operates 54 primary care clinics, four specialty/ancillary clinics, and 24 affiliate clinics in West and South Florida, with over 80,000 patients enrolled in value-based care programs, highlighting its significance in the healthcare service landscape.
- Transaction Scale: While the financial terms of the deal were not disclosed, Bloomberg reported that Humana is nearing a nearly $1 billion acquisition agreement, indicating the company's ambition to expand its healthcare service capabilities.
- Market Reaction: This acquisition comes at a time when Humana faces skepticism regarding its 2026 outlook, particularly in competition with UnitedHealth and CVS Health, suggesting the company's strategy to strengthen its market position through acquisitions to address challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HUM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HUM
Wall Street analysts forecast HUM stock price to rise
19 Analyst Rating
6 Buy
12 Hold
1 Sell
Moderate Buy
Current: 187.280
Low
231.00
Averages
290.39
High
344.00
Current: 187.280
Low
231.00
Averages
290.39
High
344.00
About HUM
Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Humana Partners to Enhance Heart Health for Medicare Advantage Members
- Partnership Expansion: Humana has announced new partnerships with CVAUSA's Novocardia Care Solutions, Karoo Health, US Heart and Vascular, and Chamber Cardio to enhance its cardiac care program, aiming to improve heart health for eligible Medicare Advantage members through value-based care.
- Enhanced Services: The new agreements provide Humana's Medicare Advantage members with 24/7 hotline access, remote monitoring tools, and integrated team support, enabling better management of heart conditions and reducing hospitalization rates, thereby improving quality of life and health outcomes.
- Value-Based Care Impact: Humana's analysis indicates that value-based care leads to higher quality care and better adherence to evidence-based medicine for cardiac patients, underscoring the company's commitment to delivering high-quality, whole-person care.
- Service Availability: Humana's cardiac care services are now available across multiple states, including Florida, Georgia, South Carolina, Illinois, North Carolina, Iowa, Arizona, Alabama, Mississippi, Louisiana, Maryland, and Texas, ensuring that more members can benefit from these enhanced services.
See More
Humana Expands Partnerships to Enhance Heart Health for Medicare Advantage Members
- Expansion of Cardiac Partnerships: Humana has signed new agreements with Karoo Health, US Heart and Vascular, and Chamber Cardio, further enhancing its cardiac care collaboration with CVAUSA's Novocardia Care Solutions to provide comprehensive heart health services for eligible Medicare Advantage members.
- Commitment to Value-Based Care: Humana emphasizes its leadership in value-based care, aiming to improve quality of life and reduce hospitalizations for cardiac patients through integrated, coordinated, and evidence-based care, thereby enhancing overall health outcomes.
- Enhanced Member Services: Eligible Humana Individual and Group Medicare Advantage members will gain access to improved cardiac care services through participating cardiologists, designed to meet their personalized needs and assist in better heart condition management.
- Whole-Person Health Strategy: Humana is dedicated to delivering high-quality, whole-person care through its insurance services and CenterWell healthcare services, aiming to drive better health outcomes and improve the quality of life for Medicare and Medicaid beneficiaries.
See More
Novo Nordisk Plans Major Price Cuts for Drugs
- Price Reduction Announcement: Novo Nordisk plans to cut the monthly list prices of its obesity and diabetes drugs by up to 50% starting in 2027, setting a new price of $675 per month to enhance accessibility for insured patients.
- Targeting Insured Patients: The price cuts specifically target insured patients whose out-of-pocket costs are linked to list prices, with commercial insurance patients potentially paying as little as $25 per month, thereby improving Novo's competitiveness in the GLP-1 market.
- Impact of Medicare Changes: This pricing strategy aligns with new Medicare prices set to take effect in 2027, where negotiated prices for Wegovy, Ozempic, and Rybelsus will be $274 per month, further alleviating patient costs.
- Industry Response: Novo's price reduction responds to market demands for lower drug prices, aiming to eliminate cost barriers and allow more patients to realize the benefits of Wegovy and Ozempic, while also reflecting the ongoing pricing competition with Eli Lilly.
See More
Market Rotation and Healthcare Sector Outlook
- Market Milestones: The S&P 500 recently hit the 7,000 mark but failed to close above it, indicating market fragility at high levels, which could affect investor confidence and lead to short-term volatility.
- Sector Leadership Shift: In 2026, sectors like energy, materials, and staples have shown impressive gains of 22.5%, 16.9%, and 13.3%, respectively, but these sectors typically lead near market tops, suggesting current leadership may lack sustainability.
- Healthcare Sector Recovery: The healthcare ETF (XLV) is up only 1.9% year-to-date, yet major components like Merck, Johnson & Johnson, and Amgen are trading near 52-week highs, indicating potential upside and positioning it as a likely next market leader.
- Investment Strategy Adjustment: Investors should focus on the healthcare sector's technical breakout, particularly the crucial $160 level; if cleared, upside targets could reach the mid-180s, signaling increasing investment opportunities in the healthcare sector within the current market environment.
See More
Naya Capital Acquires Significant Stake in Masimo
- New Investment Disclosure: Naya Capital Management UK Ltd disclosed on February 18 that it acquired nearly 1.6 million shares of Masimo, valued at approximately $203 million, indicating strong confidence in the company.
- Asset Allocation Insight: This investment represents 15.3% of Naya Capital's 13F assets under management, positioning Masimo as one of only five reportable holdings, highlighting its significance in the firm's portfolio.
- Market Performance Comparison: Despite Masimo's stock declining 2.6% over the past year, it surged over 34% on February 17 after Danaher announced a $9.9 billion acquisition at $180 per share, showcasing a dramatic price increase from $130.15.
- Investment Risk Advisory: While Naya Capital's timing appears fortuitous, the uncertainty surrounding the acquisition poses significant downside risks for investors, suggesting a cautious approach and potential recommendation to hold off on purchasing shares.
See More
Naya Capital Initiates Position in Masimo with 1.6 Million Shares
- New Position: Naya Capital Management initiated a position in Masimo (NASDAQ:MASI) by purchasing approximately 1.6 million shares valued at nearly $203 million, representing 15.3% of the fund's 13F assets under management.
- Portfolio Overview: Naya Capital's portfolio consists of only five reportable holdings totaling over $1.3 billion, with Masimo being the fifth-largest position, indicating a significant commitment to the company.
- Market Performance: Despite Masimo's shares declining by 2.6% over the past year, they surged by over 34% on February 17 following Danaher's announcement to acquire the company for $9.9 billion, raising the stock price from $130.15 to $174.69.
- Investment Risk Advisory: While Naya Capital's timing appears fortunate, analysts caution that there is considerable downside risk if the acquisition deal fails, suggesting investors should proceed with caution before buying Masimo shares.
See More
Humana Partners to Enhance Heart Health for Medicare Advantage Members
- Partnership Expansion: Humana has announced new partnerships with CVAUSA's Novocardia Care Solutions, Karoo Health, US Heart and Vascular, and Chamber Cardio to enhance its cardiac care program, aiming to improve heart health for eligible Medicare Advantage members through value-based care.
- Enhanced Services: The new agreements provide Humana's Medicare Advantage members with 24/7 hotline access, remote monitoring tools, and integrated team support, enabling better management of heart conditions and reducing hospitalization rates, thereby improving quality of life and health outcomes.
- Value-Based Care Impact: Humana's analysis indicates that value-based care leads to higher quality care and better adherence to evidence-based medicine for cardiac patients, underscoring the company's commitment to delivering high-quality, whole-person care.
- Service Availability: Humana's cardiac care services are now available across multiple states, including Florida, Georgia, South Carolina, Illinois, North Carolina, Iowa, Arizona, Alabama, Mississippi, Louisiana, Maryland, and Texas, ensuring that more members can benefit from these enhanced services.
See More
Humana Expands Partnerships to Enhance Heart Health for Medicare Advantage Members
- Expansion of Cardiac Partnerships: Humana has signed new agreements with Karoo Health, US Heart and Vascular, and Chamber Cardio, further enhancing its cardiac care collaboration with CVAUSA's Novocardia Care Solutions to provide comprehensive heart health services for eligible Medicare Advantage members.
- Commitment to Value-Based Care: Humana emphasizes its leadership in value-based care, aiming to improve quality of life and reduce hospitalizations for cardiac patients through integrated, coordinated, and evidence-based care, thereby enhancing overall health outcomes.
- Enhanced Member Services: Eligible Humana Individual and Group Medicare Advantage members will gain access to improved cardiac care services through participating cardiologists, designed to meet their personalized needs and assist in better heart condition management.
- Whole-Person Health Strategy: Humana is dedicated to delivering high-quality, whole-person care through its insurance services and CenterWell healthcare services, aiming to drive better health outcomes and improve the quality of life for Medicare and Medicaid beneficiaries.
See More
Novo Nordisk Plans Major Price Cuts for Drugs
- Price Reduction Announcement: Novo Nordisk plans to cut the monthly list prices of its obesity and diabetes drugs by up to 50% starting in 2027, setting a new price of $675 per month to enhance accessibility for insured patients.
- Targeting Insured Patients: The price cuts specifically target insured patients whose out-of-pocket costs are linked to list prices, with commercial insurance patients potentially paying as little as $25 per month, thereby improving Novo's competitiveness in the GLP-1 market.
- Impact of Medicare Changes: This pricing strategy aligns with new Medicare prices set to take effect in 2027, where negotiated prices for Wegovy, Ozempic, and Rybelsus will be $274 per month, further alleviating patient costs.
- Industry Response: Novo's price reduction responds to market demands for lower drug prices, aiming to eliminate cost barriers and allow more patients to realize the benefits of Wegovy and Ozempic, while also reflecting the ongoing pricing competition with Eli Lilly.
See More
Market Rotation and Healthcare Sector Outlook
- Market Milestones: The S&P 500 recently hit the 7,000 mark but failed to close above it, indicating market fragility at high levels, which could affect investor confidence and lead to short-term volatility.
- Sector Leadership Shift: In 2026, sectors like energy, materials, and staples have shown impressive gains of 22.5%, 16.9%, and 13.3%, respectively, but these sectors typically lead near market tops, suggesting current leadership may lack sustainability.
- Healthcare Sector Recovery: The healthcare ETF (XLV) is up only 1.9% year-to-date, yet major components like Merck, Johnson & Johnson, and Amgen are trading near 52-week highs, indicating potential upside and positioning it as a likely next market leader.
- Investment Strategy Adjustment: Investors should focus on the healthcare sector's technical breakout, particularly the crucial $160 level; if cleared, upside targets could reach the mid-180s, signaling increasing investment opportunities in the healthcare sector within the current market environment.
See More
Naya Capital Acquires Significant Stake in Masimo
- New Investment Disclosure: Naya Capital Management UK Ltd disclosed on February 18 that it acquired nearly 1.6 million shares of Masimo, valued at approximately $203 million, indicating strong confidence in the company.
- Asset Allocation Insight: This investment represents 15.3% of Naya Capital's 13F assets under management, positioning Masimo as one of only five reportable holdings, highlighting its significance in the firm's portfolio.
- Market Performance Comparison: Despite Masimo's stock declining 2.6% over the past year, it surged over 34% on February 17 after Danaher announced a $9.9 billion acquisition at $180 per share, showcasing a dramatic price increase from $130.15.
- Investment Risk Advisory: While Naya Capital's timing appears fortuitous, the uncertainty surrounding the acquisition poses significant downside risks for investors, suggesting a cautious approach and potential recommendation to hold off on purchasing shares.
See More
Naya Capital Initiates Position in Masimo with 1.6 Million Shares
- New Position: Naya Capital Management initiated a position in Masimo (NASDAQ:MASI) by purchasing approximately 1.6 million shares valued at nearly $203 million, representing 15.3% of the fund's 13F assets under management.
- Portfolio Overview: Naya Capital's portfolio consists of only five reportable holdings totaling over $1.3 billion, with Masimo being the fifth-largest position, indicating a significant commitment to the company.
- Market Performance: Despite Masimo's shares declining by 2.6% over the past year, they surged by over 34% on February 17 following Danaher's announcement to acquire the company for $9.9 billion, raising the stock price from $130.15 to $174.69.
- Investment Risk Advisory: While Naya Capital's timing appears fortunate, analysts caution that there is considerable downside risk if the acquisition deal fails, suggesting investors should proceed with caution before buying Masimo shares.
See More
